TARSTarsus Pharmaceuticals, Inc.同业对比
Tarsus Pharmaceuticals, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TARS本股 | $3.4B#8 | — | 9.8x#11 | 7.5x#4 | 146.7%#2 | 43.1%#5 | -15.7%#4 | -19.0%#6 | -33.0%#5 | — | 53.5%#8 | — |
| IMVT | $7.5B#1 | — | 10.2x#12 | — | — | -22.2%#9 | — | -68.8%#13 | — | — | 138.2%#5 | — |
| CGON | $6.6B#2 | — | 6.4x#10 | 1627.1x#10 | 254.7%#1 | -82.9%#14 | -4722.1%#9 | -15.6%#5 | -18.8%#3 | — | 107.2%#7 | — |
| SRRK | $6.0B#3 | — | 23.7x#13 | — | — | -53.7%#12 | — | -148.9%#14 | -2854.7%#7 | — | 52.7%#9 | — |
| CRSP | $5.0B#4 | — | 2.9x#3 | 1438.0x#9 | -90.6%#10 | -58.8%#13 | -18933.6%#10 | -33.3%#8 | -32.6%#4 | — | -14.6%#14 | — |
| IOVA | $4.5B#5 | — | 6.1x#9 | 17.0x#6 | 60.6%#5 | -5.1%#7 | -153.1%#6 | -53.1%#11 | — | — | 329.3%#3 | — |
| ADPT | $4.4B#6 | — | 30.9x#14 | 16.0x#5 | 54.8%#6 | 62.7%#3 | -20.6%#5 | -41.6%#9 | — | — | 114.7%#6 | — |
| RLAY | $4.1B#7 | — | 4.6x#6 | 269.0x#8 | 53.4%#7 | 18.1%#6 | -1971.6%#8 | -31.1%#7 | — | — | 357.0%#2 | — |
| DNLI | $3.2B#9 | — | 3.8x#4 | — | — | -21.2%#8 | — | -61.4%#12 | — | — | 51.5%#10 | — |
| RVMDW | $2.8B#10 | — | 1.1x#1 | — | — | -88.5%#15 | — | -43.4%#10 | — | — | 4197.3%#1 | — |
| BEAM | $2.4B#11 | — | 2.2x#2 | 17.1x#7 | 120.0%#3 | 78.8%#2 | -274.6%#7 | -7.5%#4 | -40.5%#6 | — | 0.9%#13 | — |
| BCRX | $2.2B#12 | — | — | 2.5x#1 | 94.1%#4 | 396.9%#1 | 39.0%#1 | — | — | — | 9.2%#12 | — |
| KOD | $2.1B#13 | — | 33.7x#15 | — | — | -30.5%#11 | — | -376.4%#15 | — | — | 250.3%#4 | — |
| VCEL | $2.1B#14 | 83.7x#2 | 5.6x#8 | 7.5x#3 | 16.5%#9 | 59.4%#4 | 4.0%#3 | 4.5%#2 | 4.0%#2 | 7#1 | 20.9%#11 | — |
| ADMA | $2.0B#15 | 12.7x#1 | 4.9x#7 | 3.9x#2 | 19.6%#8 | -25.7%#10 | 37.5%#2 | 36.0%#1 | 32.9%#1 | 5#2 | -43.3%#15 | — |
| COAG | $1.9B#16 | — | 4.2x#5 | — | — | — | — | 0.0%#3 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议